First successful comparison of Quantum Blue® rapid TDM assay standardization with WHO international standard for infliximab

Eva Keller1, Peter Spies2, Florian Frei1, Valeria Eckhardt1, Thomas Schuster1, Michael Schneider1
1BÜHLMANN Laboratories AG, Schönenbuch, Switzerland; 2University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland

Therapeutic drug monitoring of IBD patients under anti-TNF therapy is based on trough level determination of the drug. Rapid assays and multiple ELISAs are available that measure anti-TNF biologics. An international standard is required to improve comparability among different assays. Recently, WHO introduced such a standard for infliximab. Here, we evaluated the correlation of the infliximab WHO standard with BÜHLMANN Quantum Blue® Infliximab standardization.

RESULTS

Current standardization of Quantum Blue® Infliximab rapid test correlates very well with the WHO international standard for infliximab (NIBSC 16/170). This Quantum Blue® Infliximab rapid test represents a unique and modern analytical method, with valid standardization according to WHO for fast time-to-result and simplicity of usage in a more patient near medical environment.

METHODS

CONCLUSION

Correspondence: ms@buhlmannlabs.ch

Fig. 1. Calibration curve from WHO IFX reference material and BÜHLMANN calibrators: Ratio of test and control line (T/C ratio) against IFX concentration.

Fig. 2. Passing-Bablok regression analysis of serum samples analyzed with BÜHLMANN and WHO calibration.

Fig. 3. Bland-Altman analysis of serum samples analyzed with BÜHLMANN calibration curve (Test) and WHO calibration curve (Comparative).

Fig. 4. Spiking recovery analysis of serum samples measured in different ELISAs and one rapid test. Spiking recovery according to Westgard 2008.